Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $45.53 Average PT from Brokerages

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have received an average rating of “Moderate Buy” from the nineteen research firms that are presently covering the firm, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $45.53.

A number of brokerages have weighed in on APLS. HC Wainwright reiterated a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. The Goldman Sachs Group decreased their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Wedbush decreased their price target on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. JPMorgan Chase & Co. raised their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Finally, Royal Bank of Canada reduced their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research note on Monday, March 3rd.

Insider Buying and Selling

In related news, CFO Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $62,279.00. Following the completion of the transaction, the chief financial officer now directly owns 88,100 shares in the company, valued at approximately $2,528,470. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares of the company’s stock, valued at $3,482,123. This trade represents a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,934 shares of company stock valued at $1,950,261. 6.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC grew its position in Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after acquiring an additional 758 shares in the last quarter. Wolverine Asset Management LLC purchased a new position in Apellis Pharmaceuticals in the third quarter worth $27,000. True Wealth Design LLC purchased a new position in Apellis Pharmaceuticals in the third quarter worth $27,000. Signaturefd LLC grew its position in Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after acquiring an additional 918 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new position in Apellis Pharmaceuticals in the third quarter worth $56,000. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Stock Up 0.4 %

Shares of NASDAQ:APLS opened at $25.14 on Thursday. The firm has a market cap of $3.16 billion, a P/E ratio of -12.38 and a beta of 0.92. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals has a 12-month low of $23.77 and a 12-month high of $63.07. The business has a fifty day simple moving average of $28.94 and a 200 day simple moving average of $30.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. During the same period last year, the company earned ($0.73) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 45.2% compared to the same quarter last year. Analysts predict that Apellis Pharmaceuticals will post -1.7 earnings per share for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).